FATRIXGEL: universal biomaterial for 3D cell cultures
Project fact sheet
FATRIXGEL
Vertical: Customised health
Project description
The biomaterials used in researching new therapies, and regenerative and customised medicine, do not manage to recreate the micro-environments of native tissues.
For example, the drugs that work in vitro do not function in the following phase as the models do not include the necessary cell or enzymatic mechanisms.
Fatrixgel is a biomaterial that mimics the extracellular matrix of the native fabrics and, therefore, improves the efficiency of the 3D cell cultures.
This is achieved by means of a new patented tissue decellularization process that is fast, cost-effective, scalable and reproducible. Fatrixgel allows its properties to be adapted; always uses a single material; and can be used for any 3D culture protocol and process.
Tagline: Universal biomaterial for 3D cell cultures: Researching new customised therapies/medicine.
Financing needs:
Phase 1: €350,000 to set up company, CEO, commercial action, marketing, raw materials. Tecnalia manufactures the products.
Phase 2: €300,000-600,000 equipment for own manufacturing and scaling of sales internationally.
Market
Within the global 3D culture market (CAGR 15%, $6.5 billion in 2032), the target market is the scaffold-based segment, which accounted for 68% of the total in 2023.
The growth is driven by less use of animals, customised medicine and investment in R&D. The main customers are research institutes, biotechnological and pharmaceutical companies.
Technology tags
Business model
Project needs
Promoted by
Are you interested in high-tech projects capable of generating greater market impact?
Fill in this form and we will contact you if you want to take part in this initiative – either by contributing technology assets or if you are a talent promoter capable of turning them into business projects.
Related news
SAFEMOB: artificial intelligence for safer and more efficient public transport
Basque Tek Ventures backs this project that integrates AI in passenger vehicles to anticipate incidents and improve the travel experience
RECONNECT: spinal cord reconnection for people with spinal cord injuries
Basque Tek Ventures promotes this disruptive project that seeks to restore lost functions through state-of-the-art biocompatible implants
ILARGIA: AI-based platform for de novo protein design and optimisation
The project, powered by Basque Tek Ventures, promotes advanced biotechnological solutions for laboratories, academia and companies through an end-to-end approach
BEGI: on-chip 3D vision processor with back-end AI systems to enable neuromorphic DVS sensors
Basque Tek Ventures promotes this initiative to offer a new generation of three-dimensional perception in real time, more efficient and sustainable
Prospect Biotech: real-time analysis of cell cultures using light
Basque Tek Ventures is backing this project that offers an optic solution to develop and monitor advanced therapies.
Makby: 3D bioprinting software for regenerative medicine
Basque Tek Ventures is backing this initiative that will revolutionise the field of artificial biological tissues.
Konbus+: Controlled temperature and high velocity thermal spray systems
The initiative, coming under Basque Tek Ventures, provides high value-added coatings in extreme conditions in a cost-effective manner.
K-ALMA: Generative AI for reliable software tests
Basque Tek Ventures is backing this project that automates the code validations by reducing their high certification cost.
INTELLIWELD: assessment of weld quality
Basque Tek Ventures supports this initiative offering an integrated system to analyse and control process and product in welding systems.
CRIOKEEP: device for the cryogenic storage, transport and dosing of therapeutic products
Basque Tek Ventures is backing this solution to improve the effectiveness of advanced medicine therapies by lowering risks and costs.